Literature DB >> 16627392

Insulin treatment in type 1 diabetes.

Geremia B Bolli1.   

Abstract

OBJECTIVE: To present key aspects and strategies for use of insulin therapy in patients with type 1 diabetes mellitus.
METHODS: Limitations and advantages of various insulin regimens are discussed, and issues pertaining to insulin analogues are reviewed.
RESULTS: Rapid-acting insulin analogues provide better and safer postprandial glucose coverage than does human regular insulin. Premixed insulin preparations do not provide the flexibility to address the individual needs of patients adequately to control postprandial glucose excursions. Because of its peak, short duration, and high variability, NPH insulin is inappropriate for patients with type 1 diabetes and patients with type 2 diabetes who require continuous basal coverage. Continuous infusion of soluble insulin by means of an insulin pump is currently the most physiologic approach available for treatment of type 1 diabetes. Use of insulin glargine or insulin detemir with a rapid-acting insulin analogue at meals is an effective and reasonable alternative to insulin pump therapy.
CONCLUSION: Both rapid-acting and long-acting insulin analogues improve glycemic control. This improvement involves controlling hemoglobin A1c levels, reducing glucose excursions, and decreasing hypoglycemia, particularly during the night. Clinicians should prescribe insulin regimens that yield physiologic results in patients with type 1 diabetes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16627392     DOI: 10.4158/EP.12.S1.105

Source DB:  PubMed          Journal:  Endocr Pract        ISSN: 1530-891X            Impact factor:   3.443


  7 in total

1.  Basal insulin requirements on continuous subcutaneous insulin infusion during the first 12 months after diagnosis of type 1 diabetes mellitus.

Authors:  Neesha Ramchandani; Mary Kristine Ellis; Shobhit Jain; Sonal Bhandari; Henry Anhalt; Noel K Maclaren; Svetlana Ten
Journal:  J Diabetes Sci Technol       Date:  2010-05-01

2.  Reversal of diabetes through gene therapy of diabetic rats by hepatic insulin expression via lentiviral transduction.

Authors:  Matthias Elsner; Taivankhuu Terbish; Anne Jörns; Ortwin Naujok; Dirk Wedekind; Hans-Jürgen Hedrich; Sigurd Lenzen
Journal:  Mol Ther       Date:  2012-02-21       Impact factor: 11.454

3.  The artificial pancreas: how sweet engineering will solve bitter problems.

Authors:  David C Klonoff
Journal:  J Diabetes Sci Technol       Date:  2007-01

Review 4.  Clinical pharmacokinetics and pharmacodynamics of insulin glulisine.

Authors:  Reinhard H A Becker; Annke D Frick
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

5.  Anti-hyperglycaemic globulins from selected Cucurbitaceae seeds used as antidiabetic medicinal plants in Africa.

Authors:  Clautilde Mofor Teugwa; Thaddée Boudjeko; Bruno Tugnoua Tchinda; Pascaline Chouadeu Mejiato; Denis Zofou
Journal:  BMC Complement Altern Med       Date:  2013-03-18       Impact factor: 3.659

6.  Comparison of a multiple daily insulin injection regimen (glargine or detemir once daily plus prandial insulin aspart) and continuous subcutaneous insulin infusion (aspart) in short-term intensive insulin therapy for poorly controlled type 2 diabetes patients.

Authors:  Wen-Shan Lv; Li Li; Jun-Ping Wen; Rong-Fang Pan; Rui-Xia Sun; Jing Wang; Yu-Xin Xian; Cai-Xia Cao; Yan-Yan Gao
Journal:  Int J Endocrinol       Date:  2013-05-08       Impact factor: 3.257

7.  Long-Term Correction of Diabetes in Mice by In Vivo Reprogramming of Pancreatic Ducts.

Authors:  Yuhan Wang; Craig Dorrell; Willscott E Naugler; Michael Heskett; Paul Spellman; Bin Li; Feorillo Galivo; Annelise Haft; Leslie Wakefield; Markus Grompe
Journal:  Mol Ther       Date:  2018-02-21       Impact factor: 12.910

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.